Shots:

• The P-III trial involves assessing libtayo (300mg- IV- q3w) as monothx. vs CT in patients with recurrent or metastatic cervical cancer that has progressed on platinum-based CT. The companies expect the regulatory submission in 2021
• The results demonstrated a 31% reduction in the risk of death in the total population- improvement in OS- PFS- and ORR (16% vs 6%)- mDoR (16 mos. vs 7 mos.)- and 25% reduction in the risk of disease progression
• Libtayo is a fully human mAb targeting the immune checkpoint receptor PD-1 on T-cells. The use of Libtayo for advanced cervical cancer is investigational and has not been fully reviewed by any regulatory authority

  Ref: Regeneron | Image: Regeneron